Ifrah Financial Services Inc. Reduces Position in Stryker Co. (NYSE:SYK)

Ifrah Financial Services Inc. lessened its stake in shares of Stryker Co. (NYSE:SYK) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,932 shares of the medical technology company’s stock after selling 81 shares during the quarter. Ifrah Financial Services Inc.’s holdings in Stryker were worth $1,416,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Human Investing LLC purchased a new stake in shares of Stryker during the fourth quarter valued at approximately $72,000. Sanctuary Advisors LLC boosted its stake in shares of Stryker by 1.6% during the fourth quarter. Sanctuary Advisors LLC now owns 66,596 shares of the medical technology company’s stock valued at $26,001,000 after purchasing an additional 1,017 shares during the period. Catalyst Capital Advisors LLC purchased a new stake in Stryker in the fourth quarter worth $131,000. AlphaCentric Advisors LLC purchased a new stake in Stryker in the fourth quarter worth $619,000. Finally, Principal Financial Group Inc. lifted its stake in Stryker by 5.9% in the fourth quarter. Principal Financial Group Inc. now owns 421,968 shares of the medical technology company’s stock worth $151,930,000 after acquiring an additional 23,546 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

SYK opened at $385.05 on Monday. The business has a fifty day moving average of $377.31 and a 200 day moving average of $367.19. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market cap of $146.79 billion, a P/E ratio of 49.62, a PEG ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is 43.30%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Evercore ISI raised their price target on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Wells Fargo & Company raised their price target on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Citigroup raised their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group raised their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Finally, UBS Group raised their price target on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $420.68.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.